HER2 Monoclonal Antibody(3C9)

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding d

Introducing the HER2 Monoclonal Antibody (3C9), a cutting-edge pharmaceutical product designed to target and inhibit the overexpression of the HER2 protein. This meticulously developed antibody showcases exceptional specificity and affinity towards the HER2 receptor, making it an invaluable tool in the field of oncology.

The HER2 Monoclonal Antibody (3C9) is meticulously engineered using state-of-the-art technology, ensuring its superior quality and efficacy. Its unique composition enables it to selectively bind to the HER2 protein, effectively blocking its signaling pathways and impeding the growth and proliferation of cancer cells.

This groundbreaking antibody offers a multitude of benefits, including its ability to enhance the effectiveness of chemotherapy and radiation therapy. By specifically targeting the HER2 receptor, it aids in sensitizing cancer cells to these conventional treatments, thereby augmenting their therapeutic outcomes.

Furthermore, the HER2 Monoclonal Antibody (3C9) exhibits remarkable stability and durability, ensuring its longevity and reliability in various clinical settings. Its exceptional specificity minimizes the risk of off-target effects, thereby maximizing patient safety and minimizing potential adverse reactions.

In addition to its clinical applications, the HER2 Monoclonal Antibody (3C9) also holds immense potential for research purposes. Its precise targeting of the HER2 protein allows for comprehensive investigations into the underlying mechanisms of HER2-driven cancers, paving the way for novel therapeutic strategies and advancements in the field.

With its unrivaled precision, stability, and versatility, the HER2 Monoclonal Antibody (3C9) stands as a groundbreaking pharmaceutical product that promises to revolutionize the treatment landscape for HER2-positive cancers. Embrace the future of oncology with this exceptional antibody, and unlock new possibilities in the fight against cancer.